Telix Pharmaceuticals to hold shareholder meeting on ITM Isotope Technologies Munich acquisition

Telix Pharmaceuticals will convene an extraordinary general meeting in November 2026 for shareholders to vote on the proposed acquisition of ITM Isotope Technologies Munich. The deal involves an upfront consideration of USD 1.65 billion, comprising approximately USD 1.25 billion in Telix shares and the assumption of USD 302 million in net debt, along with closing adjustments. The agenda also includes potential contingent consideration of up to USD 700 million, contingent on FDA approvals and ITM-11 sales milestones.